BUY Aurobindo Pharma — Ajit Mishra, Religare
byAjit Mishra, ReligareHorizon: NA (inferred Swing (≤2wk))10 Jun 2026via ET Now
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days
Advisor consensus · same horizon·23 Jun · today
Aurobindo Pharma USA has received approval from the FTC to acquire Lannett Company, a significant strategic move for the company.
NSE · Press Release·22 Jun · yesterday
Aurobindo Pharma USA, a subsidiary of Aurobindo Pharma Ltd, has received FTC approval to acquire Lannett Company LLC for $250 million. This acquisition is expected to be immediately accretive to earni
BSE · Company Update·22 Jun · yesterday
2 advisors have active short-term BUY calls on this stock, with 1 issued in the last 14 days
Advisor consensus · adjacent horizon·22 Jun · yesterday
Aurobindo Pharma Ltd has received final US FDA approval for its Tafacitinib tablets in 5 mg and 10 mg strengths. This approval is a significant regulatory milestone for the company's pharmaceutical pr
BSE · Company Update·4 Jun · 3w ago
Nothing found in this tip’s window yet.
Nothing found in this tip’s window yet.
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.